Twelve patients with smouldering or indolent multiple myeloma (MM) received 12 courses of intravenous pamidronate as a single agent to evaluate both the antitumour and bone metabolism effects. One patient achieved minor response, eight had stable disease, and three - all indolent MM - showed disease progression. Serum interleukin 6 (IL-6), IL-1beta and Oncostatin-M remained stable throughout the study, while tumour necrosis factor-alpha increased. Bone density significantly increased after four and 12 courses compared with baseline. Markers for bone resorption and bone formation decreased with treatment. These results suggest that pamidronate treatment reduces bone turnover in smouldering or indolent MM, but has no significant antitumour effect.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2141.2002.03549.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Centrilobular nodules are predictive chest computed tomography (CT) findings related to adult T-cell leukemia/lymphoma development in human T-lymphotropic virus type I carriers.
Clin Radiol
December 2024
Department of Hematology, Oita Prefectural Hospital, Oita, Japan.
Aim: To evaluate predictive chest computed tomography (CT) findings associated with the development of adult T-cell leukemia/lymphoma (ATLL) in human T-lymphotropic virus type I (HTLV-1) carriers.
Materials And Methods: This retrospective study examined 171 adult T-cell leukemia/lymphoma and 158 HTLV-1 carriers who were treated from November 2004 to April 2021. The radiological features of 888 chest CT scans in total were retrospectively assessed by two chest radiologists who were unaware of the underlying diagnoses and compared between the groups.
Diagnosis and Risk Stratification in Waldenström Macroglobulinemia.
J Natl Compr Canc Netw
September 2024
Division of Hematology, Mayo Clinic, Rochester, MN.
Article Synopsis
- * Symptoms can vary widely among patients, with some being asymptomatic at diagnosis (classified as smoldering WM), while others may experience serious complications like hyperviscosity or bleeding disorders.
- * The prognosis for WM patients can be affected by factors such as age, serum lactate dehydrogenase levels, and serum albumin levels, and recent genetic discoveries have provided new insights into the biology of the disease and its potential outcomes.
MASTering systemic mastocytosis: Lessons learned from a large patient cohort.
J Allergy Clin Immunol Glob
November 2024
Department of Allergy, Kaiser Permanente Medical Center, San Diego, Calif.
Article Synopsis
- Systemic mastocytosis (SM) is a rare disease affecting about 32,000 people in the U.S., often misdiagnosed due to vague symptoms and the necessity for invasive tests.
- A study of 116 patients revealed that the majority had indolent SM, with a significant average delay of 58.3 months for diagnosis, and some patients progressed to more advanced forms.
- The findings emphasize the need for better awareness and understanding of SM to improve diagnosis and treatment, suggesting that further studies are necessary to establish effective follow-up care for patients.
An overview of prognostic markers in patients with CLL.
Front Oncol
May 2024
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Chronic lymphocytic leukemia (CLL) is a low-grade B-cell lymphoproliferative disorder. It is the most prevalent type of leukemia in the western countries, with a median age at diagnosis of 70 years. In 2023, it is estimated that there will be 18,740 new cases of CLL, and an estimated 4,490 people will die of this disease.
View Article and Find Full Text PDFGenomic Profiling to Contextualize the Results of Intervention for Smoldering Multiple Myeloma.
Clin Cancer Res
October 2024
Myeloma Institute, Sylvester Comprehensive Cancer Center, University of Miami, Miami, Florida.
Article Synopsis
- Early intervention for high-risk smoldering multiple myeloma (HR-SMM) leads to significant and lasting treatment responses, although it's uncertain if these are due to simpler disease characteristics or inaccuracies in patient classification.
- A study analyzing genomic data from 54 HR-SMM patients suggests that the genetic features of treated HR-SMM are generally less complex compared to newly diagnosed multiple myeloma, with fewer mutations affecting key genes.
- Despite some patients showing genomic complexity and experiencing treatment resistance, standard clinical risk scores are not effective in distinguishing between less aggressive and more severe disease forms, highlighting the potential for personalized therapy based on genomic profiling.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!